The firm will use the award to develop silica nanomaterial for use with many sample types, including blood, cultured cells, and pathogens.
The company believes it can make oligonucleotide synthesis faster and cheaper than currently available methods, and plans to launch a platform in the next year.
The company is developing a cloud-based platform for the detection, quantification, and interpretation of alternative splicing variation from NGS data.
The technology will allow scientists or clinicians to load crude blood sample and generate DNA sequencing libraries in a fully automated workflow.
The company is developing multiplexed and reverse-phase array versions of its protein phosphorylation-detection technology.
The company aims to use the funding to further optimize the technology and support an ongoing early-access program with beta testers.
The company said the library will be made freely available to academic and non-profit investigators through the DECIPHER Project.
The company aims to launch the qPCR-based test in sub-Saharan Africa.
The products will initially be commercialized for research applications, but the firm hopes to move into diagnostics down the road.
The two-year grant is worth $350,000 in its first year.
Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing.
Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.
Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports.
In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.